Physician profile
Ivy Carson
NPI 1023409034
$1,601.79
in general payments reported to CMS, 2019-2025
10 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $602 · 2023: $641 · 2024: $125 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $999.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $363.29 | 2022-2023 | Wegovy |
| Acadia Pharmaceuticals INC | $239.40 | 2022 | |
| Alexion Pharmaceuticals, INC. | $231.61 | 2023 | Soliris |
| Teva Pharmaceuticals USA, INC. | $132.30 | 2025 | Uzedy |
| Gilead Sciences, INC. | $125.00 | 2024 | Epclusa |
| Amgen INC. | $124.74 | 2023 | Repatha |
| Catalyst Pharmaceuticals, INC. | $121.08 | 2022 | |
| Edwards Lifesciences Corporation | $108.88 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Axsome Therapeutics, INC. | $102.15 | 2025 | Auvelity |
| Boston Scientific Corporation | $53.34 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivy Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.